Abstract
The novel benzodioxopyrrolidine (S-16924) displays a clozapine-like profile of interaction with multiple monoaminergic receptors, in addition to potent agonist activity at serotonin (5-HT)1A receptors. S-16924 (2.5 mg/kg i.p.) and clozapine (5.0 mg/kg i.p.) generated robust discriminative stimuli (DS) and displayed full mutual generalization. The D4 antagonists L-745,870 and S-18126, the D1/D5antagonist SCH-39166, and the D3 antagonist S-14297 showed at most partial generalization to S-16924 and clozapine. The D2/D3 antagonist raclopride fully generalized to S-16924, but only partially generalized to clozapine. The 5-HT2A antagonist MDL-100,907 fully generalized to S-16924 and two further 5-HT2A antagonists, fananserin and SR-46349, showed partial generalization. However, MDL-100,907, fananserin, and SR-46349 showed less pronounced generalization to clozapine. Similarly, the 5-HT2C antagonists SB-200,646 and SB-206,553 more markedly generalized to S-16924 than to clozapine. The 5-HT1A receptor agonist (±)-8-dihydroxy-2-(di-n-propylamino) tetralin generalized fully to S-16924 but not to clozapine. Full generalization was obtained to both S-16924 and clozapine for the clozapine congeners, olanzapine and quetiapine. In distinction, the benzisoxazole, risperidone, and the phenylindole, sertindole, weakly generalized to S-16924 and clozapine. However, the benzisoxazole ziprasidone, which possesses 5-HT1A agonist properties, generalized fully to S-16924 but not to clozapine. Finally, the muscarinic antagonist scopolamine generalized fully to clozapine and partially to S-16924. In conclusion, S-16924 and clozapine display both communalities and differences in their “compound” DS; this likely reflects their respective complex patterns of interaction with multiple monoaminergic receptors. Although no specific receptor was identified as underlying the clozapine DS, 5-HT1A agonist as well as D2 and 5-HT2A/2C antagonist properties contribute to the S-16924 DS.
Footnotes
-
Send reprint requests to: Dr. Mark J. Millan, Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125, Chemin de Ronde, 78290 - Croissy-sur-Seine, Paris, France.
- Abbreviations:
- AR
- adrenoceptor
- DS
- discriminative stimulus
- 5-HT
- serotonin
- RR
- response rate
- (±)-8-OH-DPAT
- (±)-8-dihydroxy-2-(di-n-propylamino)tetralin
- L-745
- 870, 3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine
- MDL-100
- 907, [R(+)-α-(2,3dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol]
- ORG-5222
- {trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
- SB-200
- 646, 1-(1-methylindol-5-yl)-3-(3-pyridyl)urea
- SB-206
- 553, 5 methyl-1-(3-pyridil-carbamoyl)1,2,3,5-tetrahydropyrrolo[2,3-f]indole
- SCH-39166
- (−)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxyl-N-methyl-5H-benzo[d]naphto-[2,1-benazazepine]
- SR-46349
- {1(Z)-[2-(dimethylamino)ethoxyimino]}-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2(E)-propene]
- (±)-S11566
- {(±)-[7-(N,N-dipropylamino)-5,6,7,8-tetrahydro-naphtho(2,3b)dihydro,2,3-furane]}
- (+)-S-14297
- {(+)-[7-(N,N-dipropylamino)5,6,7,8-tetrahydro-naphto(2,3b)dihydro,2,3-furane]}
- S-16924
- (R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluorophenyl)ethanone
- S-18126
- {2-[4-(2,3-dihydrobenzo [1,4]dioxin-6-yl)piperazin-1-yl methyl]indan- 2-yl} methanol
- WAY-100
- 635, (N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)cyclo-hexanecarboxamide
- Received July 7, 1998.
- Accepted November 24, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|